The assay detects the Glutamate dehydrogenase, produced by toxigenic and non-toxigenic strains of C. difficile.

GDH-positive patients are confirmed with a sensitive molecular assay, illumigene C. Difficile.

The combination of ImmunoCardC. difficile GDH and illumigeneC. difficile provides laboratories with an algorithmic option to C. difficile diagnostic testing.

Meridian Bioscience COO Richard Eberly said the new product, in conjunction with the Meridian illumigene C. difficile technology, empowers laboratories to identify C. difficile patients with both screening test and molecular confirmation in less than two hours.